Funding

Orthopaedic surgery
#Drug delivery #Funding #Gene therapy #Innovate UK #TherageniX #University of Nottingham

Innovate UK grant for powdered gene therapy

TherageniX and the University of Nottingham have been awarded a £995,000 ($1,252,585) grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery. Read More

#News

#ENA Respiratory #Funding #Research and development

Government funding for Phase II respiratory infection programme 

Australian clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the US Department of Defense (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations.   The new… Read More

#Business & Investment #News #Regulatory

AI brain
#Artificial intelligence (AI) #Financing #Funding #Genesis Therapeutics

AI drug discovery company closes $200m Series B financing

A Series B financing round has raised Genesis Therapeutics’ total capital to over $280 million, which will be used to bring the company’s artificial intelligence (AI)-enabled pipeline into clinical development. Genesis will also invest in continued development of generative and predictive AI methods, which form the foundation of the Genesis… Read More

#Business & Investment #News

#BioInnovation Institute #Drug discovery #Funding #Investment #Start-ups

Three therapeutics start-ups join acceleration programme

The BioInnovation Institute (BII) has welcomed three new drug discovery start-ups into its Venture Lab acceleration programme as part of its latest cohort of eight companies. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific and team development, and provides… Read More

#News #Start-up Zone

EU flag
#Brexit #Europe #Funding #Horizon Europe #Life sciences #UK government

Horizon Europe delay damaging UK’s reputation as a science leader

As negotiations continue between the UK and EU over Horizon Europe, the largest collaborative research programme in the world, the scientific research community has urged the Prime Minister to secure the UK’s membership as soon as possible.  Figures reported in The Guardian from the European… Read More

#News #Trending News

University of Bath
#Funding #Life sciences #University of Bath

£2M donated for life sciences at the University of Bath 

Scientist, pharmaceutical entrepreneur and philanthropist Professor Raymond Schinazi has donated £2 ($2.5) million to establish the first Raymond Schinazi and Family Chair of Life Sciences at the University of Bath.  The endowment will go towards the establishment of the new Department of Life Sciences, with the Department’s… Read More

#News

#Cancer research #Funding #Investment #Oncology #Paediatrics

$4.3 million awarded to advance transcription factor drugs

Talus Bio has received $4.3 million in new grants from the National Institutes for Health (NIH) and the Washington State Andy Hill CARE Fund to advance its paediatric cancer therapeutics. The Seattle-based company received two grants totalling $2.3M from the CARE Fund to fuel the discovery of new transcription factor… Read More

#Business & Investment #News

Antibodies
#Antibodies #Collaboration #Funding #Infectious diseases #LifeArc #Liverpool School of Tropical Medicine

Infectious diseases research fund will progress antibody therapies

Liverpool School of Tropical Medicine (LSTM) and LifeArc are partnering to launch a new Translational Development Fund to help tackle infectious diseases. LifeArc will invest £2.7 ($3.4) million into the fund, which will support the progression of new technologies and treatments for emerging viral threats and… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

DDW Highlights podcast: New episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

This week in drug discovery (3-7 July)  

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More

#News

AI drug discovery
#AI / data analytics / healthtech / informatics #Drug discovery #Funding #Investment #Recursion

Nvidia invests $50 million into Recursion for drug AI 

Recursion, a clinical stage company decoding biology to industrialise drug discovery, has announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE).   Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry,… Read More

#News

Great British Pounds, Investment
#Cell and Gene Therapy Catapult #Funding #Holosphere #Innovate UK

£1m grant to create VR training platform for CGT professionals 

UK technology company FourPlus, along with collaborators Holosphere and the Cell and Gene Therapy Catapult, have been awarded funding from Innovate UK to create and test a mixed reality training platform that enables customised training delivery for pharmaceutical companies and healthcare.   The project is a £1… Read More

#News

#Cancer research #Cell and Gene Therapy Catapult #Cell therapy #Funding #Innovate UK #NK:IO

£1.6m awarded to progress ovarian cancer cell therapy

NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. The funding will support preclinical development, including development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult, whose mission is to support the UK’s cell and gene therapy industry. NK:IO… Read More

#Business & Investment #News

#Camena Bioscience #Financing #Funding #Genetics / genomics #Synthetic biology

Synthetic biology company raises $10m in financing round

Camena Bioscience has closed a $10m Series A financing round, which will be used to scale operations and continue development of DNA synthesis platform gSynth. Synthetic genes are widely used by researchers to understand the mechanisms of disease, and in the drug discovery process to combat… Read More

#News

#Europe #Funding #Investment #Life sciences #Start-ups

European life sciences investor raises over €95 million

Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The company plans to invest in first and best-in-class European life science companies in drug development and digital health. The goal is to build a portfolio of 10-15… Read More

#Business & Investment #News #Start-up Zone

Financial funding
#BioCentriq #Biopharmaceuticals #Cytiva #Funding #National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) #Partnership

NIIMBL funding awarded to bring gene therapies to market faster 

Cytiva and BioCentriq, a new Jersey-based cell and gene therapy contract development and manufacturing organisation (CDMO), have been awarded funding from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership whose mission is to accelerate biopharmaceutical innovation.  Viral clearance is a key regulatory requirement… Read More

#News